Advice

In the absence of a submission from the holder of the marketing authorisation.

fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the treatment of acute deep vein thrombosis (DVT) and the treatment of acute pulmonary embolism (PE).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice29KB (PDF)

Download

Medicine details

Medicine name:
fondaparinux (Arixtra)
SMC ID:
262/06
Indication:
Acute deep vein thrombosis acute pulmonary embolism
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published:
08 May 2006